Combining Longitudinal Real-World Data and Clinical Genomics Data Will Enable a More Precise Approach to Cancer Care and Research
NEW YORK – COTA, Inc., an oncology real-world data and analytics company, today announced a new partnership with Genomic Testing Cooperative (GTC), a molecular testing company. The two companies are joining forces to integrate COTA’s deep clinical oncology real-world data with GTC’s comprehensive genomics testing data. This strategic and oncology-specific partnership, grounded in deep comprehensive clinical data, will support more precise, personalized cancer research particularly across early discovery and translational epidemiology functions.
Genomic Testing Cooperative’s innovative approach to genetic testing provides valuable molecular information, which is critical for determining the correct patient diagnosis and selecting the most appropriate treatment. GTC tissue-based and liquid biopsy testing uniquely leverages DNA and RNA sequencing for both solid and hematologic cancers to generate information on mutations, chromosomal structural abnormalities, biomarkers that can replace or complement immunohistochemistry, flow cytometry, and standard tumor markers. This comprehensive profiling is captured before treatment and frequently after relapse so a fuller picture of treatment impact on a specific patient population can be understood.
This latest partnership builds on COTA’s recent announcement with the Clinical Research Data Sharing Alliance (CRDSA) and its broader focus on bringing clarity to cancer care. Last month, COTA joined CRDSA — a collection of biopharma companies, data sharing platforms, academic institutions, and service and technology partners — focused on ushering in the next generation of data-driven healthcare.
For more information about how COTA will be integrating GTC data and other clinical genomics data assets into their real-world data platform, please visit this page.